Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados Anais da ABC (AABC) (1) BJMBR (1) Autor Andrade,J.M. (1) Buzatto,I.P.C. (1) Carrara,H.H.A. (1) GLIGOROV,JOSEPH (1) KHALIL,AHMED (1) LOTZ,JEAN-PIERRE (1) RICHARD,SANDRINE (1) Ribeiro-Silva,A. (1) SELLE,FRÉDÉRIC (1) SOARES,DANIELE G. (1) Silveira,W.A. (1) Tiezzi,D.G. (1) Mais... Palavra-chave Trastuzumab (2) Breast cancer (1) Dimerization (1) HER2/3 (1) Monoclonal antibody (1) Neoadjuvant chemotherapy (1) Pathologic complete response (1) Pertuzumab (1) Predictive factors of response (1) Prognosis (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2017 (1) 2016 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Pertuzumab and trastuzumab: the rationale way to synergy Anais da ABC (AABC) RICHARD,SANDRINE; SELLE,FRÉDÉRIC; LOTZ,JEAN-PIERRE; KHALIL,AHMED; GLIGOROV,JOSEPH; SOARES,DANIELE G.. ABSTRACT It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease, highlighting the need for new therapies. The continuous interest in novel targeted agents led to the development of pertuzumab, the first in a new class of agents, the HER dimerization inhibitors. Pertuzumab is a novel recombinant humanized antibody directed against extracellular domain II of HER2 protein that is required for the heterodimerization of HER2 with other HER receptors, leading to the activation of downstream signalling pathways.... Tipo: Info:eu-repo/semantics/article Palavras-chave: Breast cancer; Dimerization; HER2/3; Monoclonal antibody; Pertuzumab; Trastuzumab. Ano: 2016 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652016000200565 Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors BJMBR Buzatto,I.P.C.; Ribeiro-Silva,A.; Andrade,J.M.; Carrara,H.H.A.; Silveira,W.A.; Tiezzi,D.G.. The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 to 2013 and to determine possible predictive and prognostic factors. Immunohistochemistry for hormone receptors and Ki-67 was carried out. Clinical and pathological features were analyzed as predictive factors of response to therapy. For survival analysis, we used Kaplan-Meier curves to estimate 5-year survival rates and the log-rank test to compare the curves. The addition of trastuzumab to neoadjuvant chemotherapy significantly improved pCR rate from 4.8 to 46.8%, regardless of the number of preoperative trastuzumab... Tipo: Info:eu-repo/semantics/article Palavras-chave: Neoadjuvant chemotherapy; Trastuzumab; Pathologic complete response; Predictive factors of response; Prognosis. Ano: 2017 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000200702 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco